IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
07 oct. 2024 08h05 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today...
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
26 juin 2023 17h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...